MAP9

Across TCGA pan-cancer cohorts, MAP9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP9 data layer compared with 17 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MAP9 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MAP9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LUSC, and LUAD are the cancer types where MAP9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.941	0.300	.004	26	view →
LUSC	OS	Median	III,IV	0.147	0.664	.028	12	view →
LUAD	OS	Median	All	0.534	0.812	.005	8	view →
COAD	OS	Median	III,IV	0.133	0.780	<.001	6	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP9–UCEC (DFS)

Open the UCEC breakdown →